Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis

Schizophrenia Bulletin

Volumn 41, Issue 5, 2015, Pages 1162-1170

  Mondelli, Valeria ^a,b   Ciufolini, Simone ^a,b   Murri, Martino Belvederi ^a   Bonaccorso, Stefania ^a   Di Forti, Marta ^a   Giordano, Annalisa ^a   Marques, Tiago R ^a   Zunszain, Patricia A ^a,b   Morgan, Craig ^a   Murray, Robin M ^a,b   Pariante, Carmine M ^a,b   Dazzan, Paola ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cytokine; HPA axis; Inflammation; Outcome; Schizophrenia; Stress

Indexed keywords

ARIPIPRAZOLE; BIOLOGICAL MARKER; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; OLANZAPINE; QUETIAPINE; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; EARLY LIFE STRESS; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SALIVA LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; FOLLOW UP; METABOLISM; PROGNOSIS; PSYCHOTIC DISORDERS;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; INFLAMMATION; MALE; PROGNOSIS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84943196879     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv028     Document Type: Article

References (54)

1. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89:129-139.
2. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008;4:189-216.
3. Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 2011;72:1677-1684.
4. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29:671-692.
5. Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology. 2013;38:377-385.
6. Carvalho LA, Torre JP, Papadopoulos AS, et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord. 2013;148:136-140.
7. Palaniyappan L, Marques TR, Taylor H, et al. Cortical folding defects as markers of poor treatment response in first-episode psychosis. JAMA Psychiatry. 2013;70:1031-1040.
8. Reis Marques T, Taylor H, Chaddock C, et al. White matter integrity as a predictor of response to treatment in first episode psychosis. Brain. 2014;137:172-182.
9. Borges S, Gayer-Anderson C, Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology. 2013;38:603-611.
10. Belvederi Murri M, Pariante CM, Dazzan P, et al. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology. 2012;37:629-644.
11. Aiello G, Horowitz M, Hepgul N, Pariante CM, Mondelli V. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology. 2012;37:1600-1613.
12. Mondelli V, Dazzan P, Hepgul N, et al. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res. 2010;116:234-242.
13. van Venrooij JA, Fluitman SB, Lijmer JG, et al. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull. 2012;38:272-279.
14. Ciufolini S, Dazzan P, Kempton MJ, Pariante C, Mondelli V. HPA axis response to social stress is attenuated in schizophrenia but normal in depression: evidence from a meta-analysis of existing studies. Neurosci Biobehav Rev. 2014;47:359-368.
15. Breier A, Wolkowitz OM, Doran AR, Bellar S, Pickar D. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Res. 1988;25:187-194.
16. Aas M, Dazzan P, Mondelli V, et al. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol Med. 2011;41:463-476.
17. Bradley AJ, Dinan TG. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol. 2010;24:91-118.
18. Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun. 2013;31:90-95.
19. Zajkowska Z, Mondelli V. First-episode psychosis: an inflammatory state? Neuroimmunomodulation. 2014;21:102-108.
20. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014;75:307-315.
21. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
22. Tandon R, Mazzara C, DeQuardo J, et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry. 1991;29:953-964.
23. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005;30:1532-1538.
24. Garner B, Phassouliotis C, Phillips LJ, et al. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J Psychiatr Res. 2011;45:249-255.
25. McAllister CG, van Kammen DP, Rehn TJ, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152:1291-1297.
26. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998;32:9-15.
27. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology. 2008;33:693-710.
28. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA. 2007;104:1319-1324.
29. Douglas KM, Porter RJ. The effect of childhood trauma on pharmacological treatment response in depressed inpatients. Psychiatry Res. 2012;200:1058-1061.
30. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-491.
31. Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40:1509-1517.
32. Bebbington P, Nayani T. The Psychosis Screening Questionnaire. Int J Method Psych. April 1995;5:11-19.
33. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48:764-770.
34. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
35. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97.
36. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
37. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32:1903-1910.
38. Brugha TS, Cragg D. The list of threatening experiences: the reliability and validity of a brief life events questionnaire. Acta Psychiatr Scand. 1990;82:77-81.
39. Cohen S, Williamson, G. Perceived Stress in a Probability Sample of the United States. Newbury Park, CA: Sage; 1988.
40. Bifulco A, Bernazzani O, Moran PM, Jacobs C. The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. Br J Clin Psychol. 2005;44:563-581.
41. Mondelli V, Pariante CM, Navari S, et al. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr Res. 2010;119:75-78.
42. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology. 2003;28:916-931.
43. Watson S, Gallagher P, Porter RJ, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry. 2012;72:943-949.
44. Baumeister D, Russell A, Pariante CM, Mondelli V. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol. 2014;49:841-849.
45. Nitta M, Kishimoto T, Müller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39:1230-1241.
46. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414-419.
47. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181-191.
48. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31-41.
49. Tourjman V, Kouassi É, Koué MÈ, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. 2013;151:43-47.
50. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37:137-162.
51. Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol. 2009;72:67-73.
52. Clow A, Law R, Evans P, et al. Day differences in the cortisol awakening response predict day differences in synaptic plasticity in the brain. Stress. 2014;17:219-223.
53. Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology. 2012;37:956-969.
54. Zunszain PA, Anacker C, Cattaneo A, et al. Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology. 2012;37:939-949.